Israel’s TA-25 Index dropped for a second day, slipping 0.1 percent to 1,313.15 at the 4:30 p.m. close in Tel Aviv. Investors traded about 1.7 billion shekels ($472 million) in shares and convertible securities.
The following stocks rose or fell today. Symbols are in parentheses.
Bio Light Israeli Life Sciences Investments Ltd. (BOLT IT) dropped the most since June 29, sliding 8.5 percent to 0.368 shekel. The owner of companies that develop drugs and medical technology said tests of the anti-obesity drug Histalean in combination with the anti-psychotic drug Zyprexa didn’t reach the target.
Bluephoenix Solutions Ltd. (BPHX IT) jumped the most since Oct. 13, rising 4.2 percent to 6.827 shekels. The company that upgrades software packages won a contract valued at more than $1 million from an unidentified U.S. insurance group.
Brainsway Ltd. (BRIN IT) gained 4.1 percent to 7.67 shekels, the highest since Nov. 25. A unit of the developer of devices for neurological disorders received a grant from Israel’s Office of the Chief Scientist in connection with its Deep TMS system.
British-Israel Investments Ltd. (BRTS IT) increased to the highest on record, gaining 1.2 percent to 13.35 shekels. The real-estate investment company was raised to “outperform” from “market perform” at Clal Finance Brokerage Ltd.
Nova Measuring Instruments Ltd. (NVMI IT) advanced 2.2 percent to 29.30 shekels, the highest since shares began trading in Tel Aviv in June 2002. Taiwan Semiconductor Manufacturing Co. said it bought NT$514 million ($17 million) of equipment from the maker of monitoring and measurement systems since July.
Separately, Nova said it recently received $10 million in orders from an unidentified “major foundry.”
Procognia (Israel) Ltd. (PRCG IT) jumped the most since April 27, soaring 14 percent to 0.351 shekel. The drug developer signed a binding memorandum of understanding granting Euro- Diagnostica AB a license to use its technology to detect abdominal cancer.
To contact the reporter on this story: Susan Lerner in Jerusalem at Slerner2@bloomberg.net.
To contact the editor responsible for this story: Claudia Maedler at firstname.lastname@example.org